GRB2 and ovarian carcinoma: Moreover, Zhang et al. showed that miR-182-5p promotes cisplatin resistance in A2780 and SKOV3 epithelial ovarian cancer cells by targeting GRB2, as confirmed by luciferase reporter assays [68].